Cargando…

Association of the Innate Immunity and Inflammation Pathway with Advanced Prostate Cancer Risk

Prostate cancer is the most frequent and second most lethal cancer in men in the United States. Innate immunity and inflammation may increase the risk of prostate cancer. To determine the role of innate immunity and inflammation in advanced prostate cancer, we investigated the association of 320 sin...

Descripción completa

Detalles Bibliográficos
Autores principales: Kazma, Rémi, Mefford, Joel A., Cheng, Iona, Plummer, Sarah J., Levin, Albert M., Rybicki, Benjamin A., Casey, Graham, Witte, John S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3522730/
https://www.ncbi.nlm.nih.gov/pubmed/23272139
http://dx.doi.org/10.1371/journal.pone.0051680
_version_ 1782253124658921472
author Kazma, Rémi
Mefford, Joel A.
Cheng, Iona
Plummer, Sarah J.
Levin, Albert M.
Rybicki, Benjamin A.
Casey, Graham
Witte, John S.
author_facet Kazma, Rémi
Mefford, Joel A.
Cheng, Iona
Plummer, Sarah J.
Levin, Albert M.
Rybicki, Benjamin A.
Casey, Graham
Witte, John S.
author_sort Kazma, Rémi
collection PubMed
description Prostate cancer is the most frequent and second most lethal cancer in men in the United States. Innate immunity and inflammation may increase the risk of prostate cancer. To determine the role of innate immunity and inflammation in advanced prostate cancer, we investigated the association of 320 single nucleotide polymorphisms, located in 46 genes involved in this pathway, with disease risk using 494 cases with advanced disease and 536 controls from Cleveland, Ohio. Taken together, the whole pathway was associated with advanced prostate cancer risk (P = 0.02). Two sub-pathways (intracellular antiviral molecules and extracellular pattern recognition) and four genes in these sub-pathways (TLR1, TLR6, OAS1, and OAS2) were nominally associated with advanced prostate cancer risk and harbor several SNPs nominally associated with advanced prostate cancer risk. Our results suggest that the innate immunity and inflammation pathway may play a modest role in the etiology of advanced prostate cancer through multiple small effects.
format Online
Article
Text
id pubmed-3522730
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-35227302012-12-27 Association of the Innate Immunity and Inflammation Pathway with Advanced Prostate Cancer Risk Kazma, Rémi Mefford, Joel A. Cheng, Iona Plummer, Sarah J. Levin, Albert M. Rybicki, Benjamin A. Casey, Graham Witte, John S. PLoS One Research Article Prostate cancer is the most frequent and second most lethal cancer in men in the United States. Innate immunity and inflammation may increase the risk of prostate cancer. To determine the role of innate immunity and inflammation in advanced prostate cancer, we investigated the association of 320 single nucleotide polymorphisms, located in 46 genes involved in this pathway, with disease risk using 494 cases with advanced disease and 536 controls from Cleveland, Ohio. Taken together, the whole pathway was associated with advanced prostate cancer risk (P = 0.02). Two sub-pathways (intracellular antiviral molecules and extracellular pattern recognition) and four genes in these sub-pathways (TLR1, TLR6, OAS1, and OAS2) were nominally associated with advanced prostate cancer risk and harbor several SNPs nominally associated with advanced prostate cancer risk. Our results suggest that the innate immunity and inflammation pathway may play a modest role in the etiology of advanced prostate cancer through multiple small effects. Public Library of Science 2012-12-14 /pmc/articles/PMC3522730/ /pubmed/23272139 http://dx.doi.org/10.1371/journal.pone.0051680 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
spellingShingle Research Article
Kazma, Rémi
Mefford, Joel A.
Cheng, Iona
Plummer, Sarah J.
Levin, Albert M.
Rybicki, Benjamin A.
Casey, Graham
Witte, John S.
Association of the Innate Immunity and Inflammation Pathway with Advanced Prostate Cancer Risk
title Association of the Innate Immunity and Inflammation Pathway with Advanced Prostate Cancer Risk
title_full Association of the Innate Immunity and Inflammation Pathway with Advanced Prostate Cancer Risk
title_fullStr Association of the Innate Immunity and Inflammation Pathway with Advanced Prostate Cancer Risk
title_full_unstemmed Association of the Innate Immunity and Inflammation Pathway with Advanced Prostate Cancer Risk
title_short Association of the Innate Immunity and Inflammation Pathway with Advanced Prostate Cancer Risk
title_sort association of the innate immunity and inflammation pathway with advanced prostate cancer risk
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3522730/
https://www.ncbi.nlm.nih.gov/pubmed/23272139
http://dx.doi.org/10.1371/journal.pone.0051680
work_keys_str_mv AT kazmaremi associationoftheinnateimmunityandinflammationpathwaywithadvancedprostatecancerrisk
AT meffordjoela associationoftheinnateimmunityandinflammationpathwaywithadvancedprostatecancerrisk
AT chengiona associationoftheinnateimmunityandinflammationpathwaywithadvancedprostatecancerrisk
AT plummersarahj associationoftheinnateimmunityandinflammationpathwaywithadvancedprostatecancerrisk
AT levinalbertm associationoftheinnateimmunityandinflammationpathwaywithadvancedprostatecancerrisk
AT rybickibenjamina associationoftheinnateimmunityandinflammationpathwaywithadvancedprostatecancerrisk
AT caseygraham associationoftheinnateimmunityandinflammationpathwaywithadvancedprostatecancerrisk
AT wittejohns associationoftheinnateimmunityandinflammationpathwaywithadvancedprostatecancerrisk